Cipla Limited — Investor Meet, 03-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Cipla's Q2 FY26 saw record revenue of INR 7,589 crores (+8% YoY) and 25% EBITDA margin. Growth was diversified across India, North America ($233 million, #1 Albuterol MDI), Africa, and EMEU (record $110 million). They launched Filgrastim (US biosimilar) and Yurpeak (Tirzepatide) in India through Eli Lilly for obesity care. US pipeline targets 4 respiratory, 3 peptide assets by CY26. Q3 Revlimid contribution will be minimal. FY26 EBITDA margin guidance revised to 22.75%-24% due to increased R&D. Achin Gupta assumes CEO role, focused on strategic growth and pipeline expansion.